Titre:
  • A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
Auteur:Martin, Miguel; Bonneterre, Jacques; Geyer Jr., Charles C.E.; Ito, Yoshinori; Ro, Jungsil; Lang, Istvan; Kim, Sung-Bae; Germa, Caroline; Vermette, Jennifer; Wang, Kenneth; Wang, Kongming; Awada, Ahmad
Informations sur la publication:European journal of cancer, 49, 18, page (3763-3772)
Statut de publication:Publié, 2013-12
Sujet CREF:Cancérologie
Mots-clés:Breast
phase II
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- pathology
Deoxycytidine -- administration & dosage -- adverse effects -- analogs & derivatives
Diarrhea -- chemically induced
Disease-Free Survival
Drug Administration Schedule
Female
Fluorouracil -- administration & dosage -- adverse effects -- analogs & derivatives
Humans
Kaplan-Meier Estimate
Middle Aged
Nausea -- chemically induced
Quinazolines -- administration & dosage -- adverse effects
Quinolines -- adverse effects -- therapeutic use
Receptor, ErbB-2 -- metabolism
Treatment Outcome
Vomiting -- chemically induced
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2013.07.142
info:pii/S0959804913007181
info:scp/84888004978
info:pmid/23953056